GlassScriptPhysician profile
Andrew W Smith
NPI 1073875464
$1,586.84
in general payments reported to CMS, 2019-2025
20 companies · $555 in 2025
The $555 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $18.68 · 2021: $272 · 2022: $55.27 · 2023: $131 · 2024: $315 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $393.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $278.97 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $146.75 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $119.68 | 2019-2025 | Farxiga, Airsupra, Brilinta |
| Abbott Laboratories | $114.83 | 2022-2024 | Cardiomems |
| Bayer Healthcare Pharmaceuticals INC. | $97.19 | 2023-2025 | |
| Abbvie INC. | $95.13 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $62.57 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.54 | 2025 | Caplyta |
| Dexcom, INC. | $43.24 | 2024-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $34.12 | 2021 | |
| Xeris Pharmaceuticals, INC. | $23.22 | 2025 | Gvoke Hypopen |
| Collegium Pharmaceutical, INC. | $19.44 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $19.39 | 2025 | Camzyos |
| Alnylam Pharmaceuticals INC. | $18.63 | 2024 | Amvuttra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $17.93 | 2021 | |
| Exact Sciences Corporation | $14.93 | 2025 | The Cologuard Plus Collection Kit |
| Amgen INC. | $14.10 | 2025 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.02 | 2019 | |
| Becton, Dickinson and Company | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.